Risultati di ricerca
21 ore fa · Sergey Brin scommette sugli psichedelici e appoggia una start up che sta sviluppando un allucinogeno dagli arbusti della foresta pluviale per curare i problemi mentali. Catalyst4, il veicolo di ...
21 ore fa · di Ansa 22-07-2024 - 16:38. (ANSA) - ROMA, 22 LUG - Sergey Brin scommette sugli psichedelici e appoggia una start up che sta sviluppando un allucinogeno dagli arbusti della foresta pluviale per curare i problemi mentali. Catalyst4, il veicolo di investimento no profit che usa i guadagni realizzati da Brin con la vendita della sua quota in Tesla ...
21 ore fa · Google co-founder Sergey Brin invests $15M in psychedelic biotech Soneira to develop ibogaine for mental health treatment, marking a new trend in Silicon Valley's interest in psychedelics.
21 ore fa · Meanwhile, Brin, who is considered the world's seventh richest person, has so far invested hundreds of millions of dollars in neurodegenerative research and mental health research through Catalyst 4. Forbes, a U.S. economic media outlet, reported that in 2004, Brin discovered that he had a mutated gene that increased his risk of Parkinson's disease.
21 ore fa · Basics. Google hacking involves using operators in the Google search engine to locate specific sections of text on websites that are evidence of vulnerabilities, for example specific versions of vulnerable Web applications. A search query with intitle:admbook intitle:Fversion filetype:php would locate PHP web pages with the strings "admbook ...
21 ore fa · Over the past two decades, many of the winners have gone on to become industry leaders. They include Zhuang Xiaowei, a bio-imaging technology pioneer; Larry Page and Sergey Brin, founders of Google; JB Straubel, co-founder of Tesla; and Zhang Feng, inventor of CRISPR gene editing technology.
23 lug 2024 · Google co-founder Brin backs biotech tapping psychedelic shrub for remedies Google co-founder Sergey Brin is bankrolling the development of a hallucinogen derived from a rainforest shrub for use as a mental health treatment, in the latest Silicon Valley deal in the nascent psychedelics sector.
